Paul O'Sullivan has already notched his benchmark wins for the campaign but his season is a long way from over with promising Gideon putting himself up as a horse to follow after getting his act together quickly.
Like many first starters who have shown talent at the trials, and particularly those who will be looking for further as their careers progress, the 1,000m straight course had Gideon bamboozled when he made his racecourse debut last month.
With the state of the straight course these days, no failure there should be held against any horse and Gideon found the 1,200m around a bend a better venue on the weekend, even with the tempo very much against him.
Karis Teetan cleverly controlled the speed on leader Medic Kingdom, not by stacking them up in a slow middle section but by gradually increasing the tempo each section of the race, which meant horses running on didn't get to pull back any ground cheaply.
It's a race shape that is tough to overcome for the finishers and the second, third and fourth placegetters all did well to take ground off Medic Kingdom but Gideon is the least exposed of the three and had already shown some proper talent in his trials both here and in New Zealand.
By O'Reilly out of a Pins mare, Gideon was bred by the O'Sullivan family, has a pedigree destined to succeed in Hong Kong and will certainly pay his way into Class Three and possibly beyond.
In the final race, John Moore-trained Travel Brother was the horse to catch the eye going forward as he got to the line well in fourth place behind Flame Hero.
The four-year-old will probably find his way into the Derby and just as likely find Designs On Rome and Able Friend too strong there, but he is a colt with his foot on the till and who will find at least a minor feature race within his scope based on what he was able to achieve in England as Van Der Neer.
A winner on polytrack and turf and well performed to 2,000m, he looks versatile and talented and will surprise if he doesn't have at least another 15 ratings points in him as his career develops.